Indian Journal of Public Health Research & Development

Shashank Shekhar Gautam ¹, Gunjeet Singh ²

Affiliations
1 Senior Resident, Dept. of Pharmacology MMIMSR, MMDU, Mullana, Ambala, IN
2 Post Graduate Junior Resident, Dept. of Pharmacology MMIMSR, MMDU, Mullana, Ambala, IN

Abstract

Fibromyalgia is a chronic condition with unknown aetiology. Fibromyalgia is characterized by chronic widespread pain and several additional symptoms such as fatigue, cognitive dysfunction, depressive episodes and anxiety. The underlying pathophysiology of fibromyalgia is still poorly understood and treatment is often unsatisfactory. Current treatments include drugs that target serotonin and noradrenaline levels within the central nervous system, e.g., tricyclic antidepressants, serotonin noradrenaline reuptake inhibitors and voltage-gated calcium channel subunit ligands, e.g., gabapentin and pregabalin. Investigation of a range of novel targets, such as melatoninergic, cannabinoid, dopamine, NMDA, angiotensin, orexin and opioid receptors and ion channels, in addition revisiting bioamine modulation and subunits has provided efficacy outcomes that improve the health status of patients with FM. Nevertheless, modest and limited efficacy is often observed reflecting the heterogeneity of FM with existence of subpopulations of patients, the contribution of peripheral and central components to the pathophysiology and the extensive range of accompanying co-morbidities. The complexity and multidimensional nature of FM is emphasized by the diversity of pharmacological targets gaining interest. Clues to underlying mechanisms which offer themselves as novel and potential targets for new medications are being provided by advances in the understanding of the pathophysiology of FM.

Keywords

Fibromyalgia, chronic pain,fatigue, NMDA receptors, melatonin receptors, gabapentanoids.

Full Text